VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PRQR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PRQRProQR Therapeutics N.V.
$1.10$116M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. PRQR
  4. Financial Ratios

ProQR Therapeutics N.V. (PRQR) Financial Ratios

Latest Ratios: P/E Ratio -2.6x · EV/EBITDA N/A · ROE -54.1%. (2013–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

PRQR Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$116M$213M$216M$160M$265M$514M$210M$407M$537M$82M$114M
Enterprise Value$15M$121M$78M$51M$187M$370M$159M$296M$425M$33M$57M
P/E Ratio →-2.60——————————
P/S Ratio5.6813.9311.4524.6273.75385.09204.33210.39108.75—50.13
P/B Ratio1.823.672.363.513.723.993.043.865.071.742.04
P/FCF———7.95———————
P/OCF———7.44———————

P/E links to full P/E history page with 30-year chart

PRQR EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—7.904.117.8052.13276.78154.91153.2585.95—24.89
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———2.52———————

PRQR Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin83.0%83.0%100.0%100.0%100.0%100.0%100.0%-5943.6%80.1%165.5%43.8%
Operating Margin-275.9%-275.9%-161.2%-489.1%-1813.0%-4285.4%-4117.4%-2971.8%-734.5%2648.7%-1734.1%
Net Profit Margin-265.2%-265.2%-146.9%-431.7%-1792.5%-4549.8%-4525.3%-2935.6%-746.7%2854.0%-1713.5%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-54.1%-54.1%-40.4%-48.1%-64.4%-61.4%-53.4%-53.7%-48.2%-84.5%-53.6%
ROA-26.5%-26.5%-17.0%-16.8%-30.6%-33.8%-36.8%-44.0%-38.9%-65.7%-46.2%
ROIC—————-3430.3%-480.7%————
ROCE-37.0%-37.0%-24.6%-23.2%-35.5%-36.3%-37.2%-48.6%-42.6%-70.1%-50.5%

PRQR Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.280.280.180.480.330.530.610.140.080.180.09
Debt / EBITDA———————————
Net Debt / Equity—-1.59-1.51-2.40-1.09-1.12-0.73-1.05-1.06-1.04-1.03
Net Debt / EBITDA———————————
Debt / FCF———-5.43———————
Interest Coverage-45.75-45.75-24.96-22.12-11.50-16.82-24.90-159.14-44.78-67.95-69.16

Net cash position: cash ($109M) exceeds total debt ($16M)

PRQR Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio3.093.093.953.547.366.947.7710.4313.285.959.24
Quick Ratio3.093.093.953.547.366.947.7710.4313.285.959.24
Cash Ratio2.852.853.843.484.526.807.3610.1812.945.668.82
Asset Turnover—0.120.110.040.020.010.010.010.04-0.020.03
Inventory Turnover———————————
Days Sales Outstanding—142.7040.5278.496203.69255.89347.21252.23180.88-134.44264.02

PRQR Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———12.6%———————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$105M$82M$81M$72M$64M$50M$41M$34M$25M$23M

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetHealthy
Cash FlowBurning
Top Statement Risk

Shrinking cash runway versus persistent burn

Premium Book Multiple Against Losses

Based on reported figures, PRQR trades at 8.33 times sales and 2.19 times book with a trailing P/E of -3.18, a pricing structure that rests on pipeline value rather than current earnings power.

With no positive earnings and no free cash flow yield, the valuation cannot be anchored to conventional earnings or cash multiples, so the 2.19 price-to-book figure is the most usable reference point. Relative to peers such as NTLA at 1.83 and BEAM at 2.11, PRQR carries a similar or modestly higher book multiple despite a comparable loss profile. Investors should monitor whether the market continues to attribute value to the clinical pipeline as cash reserves decline, since the multiple appears to embed expectations that the reported figures do not yet demonstrate.

Operating Losses Dominate Earnings Power

As reported in the income statement, PRQR's operating margin was -100.7% in 2026Q2 and has remained deeply negative across most quarters, with net margin of -99.6% in the latest period.

Gross margin has stayed near 100% in most quarters, which reflects the collaboration revenue structure rather than a product cost base, so gross margin offers little information about true earning power. The more informative measure is operating margin, which has been consistently negative and largely driven by R&D spending that exceeds revenue in most periods. Any single quarter with elevated revenue, such as the latest, should be viewed with caution until it recurs.

Low Debt Despite Shrinking Equity Base

Based on reported figures, PRQR's debt-to-equity ratio fell to 0.17 in 2026Q2 from 0.63 in 2024Q3, though this decline reflects a shrinking equity denominator more than deliberate deleveraging.

Interest coverage is not meaningful given negative operating income, and debt servicing capacity depends on the cash balance rather than earnings. The decline in the debt ratio coincides with equity erosion from accumulated losses, so the lower ratio may overstate balance sheet strength. Refinancing or covenant risk cannot be assessed from the supplied data beyond noting the absence of interest coverage support.

Liquidity Strong on Paper, Finite in Practice

As reported in financial statements, PRQR's current ratio stood at 3.49 in 2026Q2, supported by a cash-heavy asset base, though this figure does not account for the rate at which cash is being consumed.

The quick ratio equals the current ratio because inventory is negligible, so liquidity depends almost entirely on cash and receivables rather than operating assets. Under a severe stress scenario with sustained operating cash burn, the current cushion would erode over a finite period, and the reported figures do not disclose a funded runway. Investors should monitor quarterly cash depletion against the reported balance to estimate how long the current position can sustain operations without new capital.

Ratio Most Misapplied: Gross Margin

Based on reported figures, PRQR's gross margin of 91.9% to 100.0% for most quarters is often read as a sign of pricing power, yet for a collaboration-revenue biotech it obscures the operating losses that actually define the business.

Gross margin for a collaboration-driven company reflects the absence of cost of goods sold on licensing income rather than product economics, so a high figure can mislead investors into assuming scalable profitability. Operating margin, combined with cash burn relative to reserves, is a more appropriate measure of the company's financial position. Analysts should instead track operating cash flow against cash balance to gauge the time remaining before additional financing is needed.

Download Financial Ratios Data

Includes 30+ ratios · 13 years · Updated daily

Consensus & Technical Research Suite
Open PRQR Terminal

PRQR Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

PRQR — Frequently Asked Questions

Quick answers to the most common questions about buying PRQR stock.

What is ProQR Therapeutics N.V.'s P/E ratio?

ProQR Therapeutics N.V.'s current P/E ratio is -2.6x. This places it at the 50th percentile of its historical range.

What is ProQR Therapeutics N.V.'s ROE?

ProQR Therapeutics N.V.'s return on equity (ROE) is -54.1%. The historical average is -50.4%.

Is PRQR stock overvalued?

Based on historical data, ProQR Therapeutics N.V. is trading at a P/E of -2.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are ProQR Therapeutics N.V.'s profit margins?

ProQR Therapeutics N.V. has 83.0% gross margin and -275.9% operating margin.